Cephalon Inc. said it has received a Phase II Small BusinessInnovation Research (SBIR) grant of $400,000 from theNational Institute of Mental Health of the NIH. The grant is fordeveloping proprietary research technologies capable ofidentifying compounds that promote nerve cell survival indegenerative diseases, such as Alzheimer's, the West Chester,Pa., company said.

(c) 1997 American Health Consultants. All rights reserved.